Putative neuroprotective agents in neuropsychiatric disorders

Gut Microbiota and Neuropsychiatric Disorders

Apathy in neuropsychiatric disorders

Apathy is a common neurobehavioral feature in a variety of neuropsychiatric disorders. Apathy is often interpreted as a sign of deppression or as a nonspecific symptom of other medical conditions. However, recent research indicates that the essential meaning of apathy is lack of motivation. This article presents a frame work for the classification and differential diagnosis of apathy and addres...

Autoantibodies in Neuropsychiatric Disorders

Little is known about the etiology of neuropsychiatric disorders. The identification of autoantibodies targeting the N-methyl-D-aspartate receptor (NMDA-R), which causes neurological and psychiatric symptoms, has reinvigorated the hypothesis that other patient subgroups may also suffer from an underlying autoimmune condition. In recent years, a wide range of neuropsychiatric diseases and autoan...

Proteomics in neuropsychiatric disorders.

Assessing human cerebrospinal fluid (CSF) provides a practical way to conduct longitudinal molecular analyses of changes during the course of neurological disease. Integrated and parallel analyses of neurotransmitters, neuropeptides and proteins in CSF may reveal better insights into complex interaction of numerous cell types in the central nervous system (CNS) at an unprecedented level of comp...

Neuroprotective Agents in Glaucoma

1.1 Glaucoma as a neurodegenerative disorder Glaucoma is a multifactorial disease in which multiple genetic, systemic and environmental factors interact to precipitate the disease. Increased intraocular pressure (IOP) is believed to be one of the major factors responsible for glaucomatous cell death. (Guo et al., 2005). The axons of the optic nerve make a twisting exit through the fenestrated c...